



We would like to thank all our partners and sponsors



Knowledge Partner



Gold Sponsor



Silver Sponsor



Media Partners

The logo features a stylized globe on the left, composed of green and blue segments. To its right, the letters 'CDPX' are prominently displayed. The 'C' and the first 'X' are in a dark blue color, while the 'D' and the second 'X' are in a green color. The year '2022' is positioned below the 'CDPX' text. The background is a dark blue gradient with a faint image of a laboratory setting.

US

2022

**World Series of Industry
and Investor Partnering
Conferences**

**In partnership with the
AACC Clinical Lab Expo**

**Focusing on Diagnostics, Digital Health,
Precision Medicine and Life Science Tools**

3 DAYS IN PERSON
AACC Clinical Lab Expo
McCormick Place, Chicago

July 26th - 28th, 2022
2 WEEKS DIGITAL PARTNERING
July 14th - 25th, 2022



**McDermott
Will & Emery**

HELPING LIFE SCIENCE LEADERS ACHIEVE THEIR MISSION.

We know it's mission that drives you. Whether you're a cutting-edge diagnostics start-up or a global leader in the industry, our team provides the full range of legal services to help you overcome obstacles, enter new markets and take advantage of opportunities on your path to success.

[MWE.COM/LIFESCIENCES](https://mwe.com/lifesciences)



Contents

2
Editorial

3
DxPx portrait

6
Agenda for July 26th - 28th, 2022

7
Floor plan

9
Startup City and accelerators' section

11
Panel descriptions

13
Speakers

18
Diagnostics4Life - Our charity platform

19
The 42PLUS1 Pitch Award

23
Reception and Contact

25
Outlook and save the dates 2022



Why BGL?

- Leading Independent Investment Bank
- Global Network of Investors & Buyers
- Deep Experience in Healthcare M&A
- Special Focus on Privately-Owned Businesses

Featured Transaction

LOWENCO

— acquired by —

Impilo SHS

BGL's Healthcare and Life Sciences team served as the exclusive financial advisor to Lowenco in its acquisition by Impilo and SHS, leading European private equity firms specializing in control equity investments in lower-middle market healthcare companies.

Transaction Highlights

- Lowenco is a global leading manufacturer of large-scale ultra-low temperature (ULT) storage solutions for biotech and pharmaceutical companies.
- BGL was engaged to market the sale to a comprehensive range of strategic and private equity sponsors and executed a broad marketing process.
- As a result of the completed transaction, Lowenco is well-positioned to continue addressing the increasing demand for large-scale ULT storage solutions, underpinned by the strong underlying growth in biopharma volumes.

LOWENCO

— acquired by —

Impilo SHS

**SourceBio
International plc**

— acquired by —

LDPATH

CARDIOLINE

— acquired by —

ArchiMed
Innovative & Entrepreneurial
in Healthcare



AZZUR GROUP

Growth Equity Investment

Baird Capital



John C. Riddle
Managing Director
Head of Healthcare
& Life Sciences
312.658.4758
jriddle@bglco.com



Christoph D. Brandenberger
Managing Director
Diagnostics, Research Tools
& Medical Devices
312.658.4773
cbrandenberger@bglco.com

Dear participants,

Welcome to DxPx! It is our fourth year holding the DxPx Conference, and we are happy to share this success with all of you. The past three years have been challenging for all of us globally, but we have witnessed the relevance of our industries to innovation. Looking back on our first DxPx US in 2021, we are glad to bring together so many different countries during the virtual conference. With a strong American focus, we also had participants from Canada, Germany, Belgium, France, China, the United Kingdom, Switzerland, and many more.

This year, the whole DxPx team is excited to reach another milestone which is being in person at AACC Clinical Lab Expo, in McCormick Place, Chicago for the first time. Being in the flesh in the US this year certainly paves the way for more startups, growth companies, industry leaders, and investors to join the partnering conference and develop valuable business connections. There is so much potential and we are enthusiastic to build a startup city together!

Now we want to share some information about the team who made this happen and worked for the conference to be as engaging and beneficial as can be for everyone. The founders of DxPx are all startup entrepreneurs and former industry executives who had the idea for this conference after attending numerous partnering events where the vast majority of participants and investors are focused on pharma, biotech, and drug screening opportunities. With the gaining importance of diagnostics, digital health, precision medicine, and life science tools, there's a need for a dedicated platform to bring together the relevant stakeholders and further drive our industries.

Now, how is it going? Together with the support of our knowledge partners, sponsors, and media partners, DxPx is hosted as an annual international partnering conference to facilitate licensing, financing, co-development, and M&A partnerships and celebrates great success and fast growth. In parallel, we are ecstatic that we secured the funding of our Pitch Award, 42PLUS1, to \$2,000,000 convertible loans for another round this year to support innovative startups and growth companies.

Finally, we are honored to present Diagnostics4Life, the charity platform of DxPx. With the social engagement and helpfulness of our stakeholders, founders, and investors, we would like to share this endeavor with you. To further help communities that are not yet reached by current innovation and discoveries, the DxPx team along with our partners decided to launch the DxPx charity foundation, Diagnostics4Life.

This year, DxPx US is working with Conquer Cancer™, the American Society of Clinical Oncology's foundation, for this initiative of raising awareness on conquering cancer and spreading the value our industries provide to our society. We have also been working with our chosen DxPx EU charity, Elterninitiative herzkrankter Kinder Köln by working together with the parents' initiative for children with heart disease in Cologne, Germany.


Best,
The DxPx Team

How it all started


DxPx was first launched in 2019 as a physical event managed independently, yet parallel, to the MEDICA Trade Fair in Düsseldorf, Germany. During this time, COVID was unheard of and with over 400 participants attending DxPx physically, it was a strategic decision to expand the conference and make it more accessible to different regions.

Looking back on our first DxPx US, we're happy that we've brought together so many different countries during the virtual conference. With a strong American focus, we also had participants from Canada, Germany, Belgium, France, China, the United Kingdom, Switzerland, and many more.


Represented industries



Key players



Investor types



Where we are now

Now, what's ahead for DxPx US 2022? Being in the flesh in the US this year certainly paves the way for more startups, growth companies, industry leaders, and investors to join the partnering conference and develop valuable business connections. There is so much potential and we are enthusiastic to build a startup city together at the AACC Clinical Lab Expo, McCormick Place, Chicago.

We also believe that a combination of several days of digital partnering with dedicated days for in person meetings, panel discussions, and fireside chats combines the best of two worlds. Flexibility and accessibility are factors we put into consideration in this conference. With the support of our knowledge partners Brown Gibbons Lang & Company, McDermott Will & Emery, and Silversky Life Sciences; and sponsors AACC and lino Biotech, the DxPx Conference is continuously growing and expanding.



640

DECISION-MAKERS

2100

ONE-TO-ONE MEETINGS

44

PARTICIPATING COUNTRIES

65

RENOWNED SPEAKERS

14 DAYS

**DIGITAL AND IN PERSON PARTNERING ON THE
DIAGNOSTICS, DIGITAL HEALTH, PRECISION MEDICINE
AND LIFE SCIENCE TOOLS INDUSTRIES**

Recap previous events with our


DxPx Impressions



Agenda for the in person conference

July 26th - 28th, 2022

3 days of hands-on talks at the **AACC** Clinical Lab Expo!



3 DAYS IN PERSON

AACC Clinical Lab Expo,
McCormick Place, Chicago

July 26th - 28th, 2022

2 WEEKS DIGITAL PARTNERING

July 14th - 25th, 2022

Day 1

July 26th, 2022

Day 2

July 27th, 2022

Day 3

July 28th, 2022

During all 3 days: one-to-one partnering and access to the DxPx Startup City.

9:30 am - 10:00 am

Opening Speech

Welcome speech, DxPx US 2022.

10:30 am - 11:30 am

Panel Discussion

European Startups: Undervalued opportunities for US Investors?!

12:00 pm - 1:00 pm

Panel Discussion

The future of AI in health care.

2:00 pm - 3:00 pm

Panel Discussion

Upscaling & manufacturing in Cell & Gene Therapies - Current challenges and solutions.

4:00 pm - 5:00 pm

Fireside Chat

Establishing a new diagnostics gold standard in biomarkers. The importance of clinical involvement in launching novel diagnostics to change the standard of care.

10:00 am - 11:00 am

Panel Discussion

Post-merger integrations in life sciences. The good, the bad, the ugly.

1:30 pm - 3:30 pm

Panel Discussion

Digital health funding: Staying the course in choppy waters.

1:30 pm - 3:30 pm

42PLUS1 Satellite FINALS

Watch live pitches from 8 innovative startups from the diagnostics, digital health, precision medicine, & life science tools industries.

4:00 pm - 5:00 pm

Fireside Chat

The current state and the future of single-cell tools and diagnostics.

7:00 pm - no end given

Reception

Join the legendary DxPx Reception! At the Rooftop Bar of Hiltons at McCormick Place.

9:30 am - 12:00 pm

Go Beyond

Discover exciting startups at the DxPx Startup City.

Get to know ASCO Conquer Cancer; our charity partner.

Catch up on more meetings and make the best out of this opportunity.

DxPx US - located in the heart of the AACCC Clinical Lab Expo!

Filled space: 2.000m² / 20.000 ft² & dedicated venue for panels and sessions.



DxPx Partnering Area
(one-to-one meetings)




Startup City



Dedicated Sponsors' Area



Working Area



Panels, & Sessions'



CLAIM
YOUR FREE
SUBSCRIPTION AT
**AACC.ORG/
CLNFREE**



Clinical Laboratory News Magazine.

**The name leaders trust,
from AACC's global
expertise in laboratory
medicine.**

CLN is the essential read for more than 160,000 researchers, clinical laboratorians, pathologists, industry professionals, and others in the diagnostics field.

CLN covers the insider topics that matter most to you, with expert insights on science, technology, leadership, and more.



*Better health through
laboratory medicine.*

Bigger than ever!

Welcome to the DxPx US Startup City!

Having a huge community of startups in the US is one of the reasons why we are bringing DxPx US in the flesh this year at AACC Clinical Lab Expo, Chicago, US. Exchanging ideas and talking about innovation with all these companies is a huge leap in bringing people in the same field together in one room. Of course, all startups from all over the world are welcome at the DxPx US!

Building a startup city focusing on Diagnostics, Digital Health, Precision Medicine, and Life Science Tools is what we are aiming for so that more valuable businesses grow and come to life. Matchmaking the relevant investor and industry leaders to a particular startup or growth company are one of the best outcomes of this partnering conference.

Here are the benefits of joining the DxPx US Startup City:

- Meet 100+ global investors, promote one's business, and discuss the business' potential.
- Get a kiosk (42ft²/4m²) AND one free in person ticket
- „Come as you are!“ No need to worry about set-up because it will be set up for you by us.
- Gain visibility by presenting one's company to potential future collaborators!
- BONUS: Since the DxPx Startup City is happening at the AACC Clinical Lab Expo, everyone will have the opportunity to explore 700+ exhibitors, 200+ product categories, and live demos.



- Experience one-to-one partnering and networking with promising entrepreneurs and scientists
- Connect with future collaborators and unlock new business ventures!

The best way to enhance your reach, influence and portfolio

DxPx for TTOs and Accelerators!

Bridging the investment gap: The primary role of startup accelerators is to bridge the gap between startup companies and potential investors. Accelerators offer mentorship to startup entrepreneurs. Accelerators also provide the means to improve the viability of business ventures for investors, in terms of finding the most qualified founder team or employees.

Here at DxPx we always provide the best experience for the accelerators and the startups joining. Last year we started the 42PLUS1 Pitch Award and in 2022 we are taking it to the next level by building a whole Startup City! The Startup City is limited to only 40 kiosks so that each participant gets the opportunity to network with the maximum number of investors and industry experts possible!

Most entrepreneurs find that simply being exposed to insightful mentors makes the experience worth it, although there are many more benefits to participating an accelerator and their network of startups. You might come away with new friends, potential partnerships, and possible investors, all of which will benefit any startup.

Every startup needs a group of peers they can call on, cash to keep going, and mentorship to help guide them through strategic questions at any given time. This is why, as we think about the next few months and years, accelerators are more important than ever.

Every startup needs a group of peers they can call on, cash to keep going, and mentorship to help guide them through strategic questions at any given time. This is why, as we think about the next few months and years, accelerators are more important than ever.

How does this work with DxPx:

The DxPx conference represents the ultimate “platform” for networking and partnering, bringing TTOs, accelerators, startups, and investors even closer by providing community, connections, and coaching.



DxPx US Program

Day 1

July 26th, 2022

European Startups: Undervalued opportunities for US Investors?!

Cross-border investments from US-based VCs in European startups have continuously increased over the past years. In 2021, every 5th European deal had at least one U.S. investor on board, up from 17% in 2020 and 15% in 2019. Investors and entrepreneurs on this panel will discuss the unique challenges and opportunities that result from such cross-board deals and provide tips on how to best find and attract the right partners in oversea.

The future of AI in health care.

Almost everyone considers AI applications in health care to become a game changer with major benefits on patient treatments and cost structures. Yet, regulatory approval and education of users such as physicians to trust algorithms remain challenging. In this panel we review how large-cap and smaller startups successfully overcame some of these hurdles and discuss what is needed over the next 5 years to realize more of the value that AI can offer to the health care system.

Upscaling & manufacturing in Cell & Gene Therapies Current challenges and solutions.

Cell & Gene Therapies are considered to be the next big wave in medicine. Unlike classical pharmaceuticals, these therapies heavily depend on the quality of the manufacturing process. In addition, the short shelf life of the final products makes collecting data on safety and potency a time-critical challenge. Together with industry leaders and innovative life science tools companies, we will discuss new solutions and open gaps that need to be filled to make CGTs broadly accessible.

Establishing a new diagnostics gold standard in biomarkers.

The importance of clinical involvement in launching novel diagnostics to change the standard of care. Novel diagnostic methods have the potential to change the standard of care in healthcare. In this fireside chat we review how Cardiac troponin (cTn) has become an essential part of diagnosing myocardial infarction (MI) since testing for it was introduced in the 1990s and what the lessons are for launching similar diagnostic methods.



Day 2/3July 27th / 28th, 2022

Post-merger integrations in life sciences. The good, the bad, the ugly.

Many transactions in the diagnostics & tools space are structured with a significant part of the compensation being linked to future milestones. Yet, with more than half of mergers and acquisitions failing or underperforming, it is important to learn how to increase chances for success. Bringing together two organizations, each with its own processes, culture, and management, is complex and requires full attention before and after the transaction. We learn from buyers, and entrepreneurs what to look out for and what mistakes to avoid.

42PLUS1 Pitch Award.

42PLUS1 is one of the highest prized pitch awards and part of the DxPx Conference. Supporting startups and growth companies is what drives DxPx – for that reason 42PLUS1 offers \$2,000,000 for the finalists of the grand finale, in the form of convertible loans. The grand finale will take place alongside DxPx EU in November 2022, while the Satellite 42PLUS1 Pitch Award, taking place at DxPx US, provides the winner with a spot to pitch straight at the grand finale! With a huge audience of international investors and industry executives, participating startups have the chance to make a real difference and accelerate their business.

Digital health funding: Staying the course in choppy waters.

How can an organization know that short-term price increases are fair and in line with expectations? How can companies prepare to deal with the long-term consequences of inflationary markets? No one can perfectly predict the next set of inflationary pressures, but it's reasonable to assume that they'll return eventually. Leaders can prepare now to minimize the impact when that day arrives.

The current state and the future of single-cell tools and diagnostics.

Cell & Gene Therapies are considered to be the next big wave in medicine. Unlike classical pharmaceuticals, these therapies heavily depend on the quality of the manufacturing process. In addition, the short shelf life of the final products makes collecting data on safety and potency a time-critical challenge. Together with industry leaders and innovative life science tools companies, we will discuss new solutions and open gaps that need to be filled to make CGTs broadly accessible.



Get to know the speakers

Topic: European Startups: Undervalued opportunities for US Investors?!

SEBASTIEN LATAPIE

Principal, Dynamk Capital LLC

Sebastien Latapie has worked at the intersection of healthcare and technology for the last 10 years. He started his career in academia studying immunology and biochemistry at McGill, spent four years in consulting focused on healthcare, before joining Dynamk in 2019 where he focuses on partnering with startups enabling the future of life sciences.



DYNAMK
CAPITAL

ANGUS MCQUILKEN

Industry Relationship Executive at McDermott Will & Emery

Angus McQuilken has 29 years of experience in leadership positions in communications, marketing, business development and public affairs. After nine years as the state's lead communicator in life sciences, he is now leading life sciences practice growth initiatives for McDermott Will & Emery.



McDermott
Will & Emery

MODERATOR

Topic: The future of AI in healthcare.

RICHIE BAVASSO

CEO of nQ Medical

Mr. Bavasso is one of the early pioneers of use of digital media, devices and the web as tools to support pharmaceutical sales and marketing strategies and tactics. Since 1999, he has worked with top 25 Pharma clients globally to introduce the Closed Loop Marketing (CLM) function. He has set procedure and precedent in the areas of sales force effectiveness, business-rule driven content management, multichannel marketing, and mobile technology. A frequent speaker at industry conferences and events, Mr. Bavasso serves as an advocate for the industry in promoting digital conversation as integral to the various enterprise functions within pharma and the medical community.



nQ Medical

BOBBY REDDY

CEO and Co-founder of Prenosis

Prenosis is a health tech innovator devoted to ushering in a new era of precision diagnostics in acute care using artificial intelligence. Its Immunix precision diagnostics platform leverages machine learning algorithms trained on deep biological data and broad clinical data to more holistically capture and illuminate the complex health states of patients. Its proprietary NOSIS dataset is the largest and fastest growing hybrid biomarker-clinical dataset for sepsis care. The Sepsis ImmunoScore diagnostic on the Immunix platform has the potential to save thousands of lives and billions of dollars in healthcare spending annually.



PRENOSIS

DxPx Speakers

joining DxPx US 2022!

Topic: Upscaling & manufacturing in Cell & Gene Therapies - Current challenges and solutions?

PAUL GOODWIN

Science Director, Cytiva

His role is to investigate ways to convert challenges into business opportunities, and he helps drive innovation processes within Cytiva, Pall Biotechnology, and other Danaher operating companies. He is the Past-President of The Histochemical Society and serves on several advisory councils including the Leadership Advisory Council for the Advanced Regenerative Manufacturing Institute. He is the Co-Director of the upcoming Gordon Research Conference titled "Advanced Cell and Tissue Biomanufacturing" planned for June 2023.



cytiva

EDITA BOTONJIC-SEHIC PHD

Director, Analytics at Pall Corporation

His role is to investigate ways to convert challenges into business opportunities, and he helps drive innovation processes within Cytiva, Pall Biotechnology, and other Danaher operating companies. He is the Past-President of The Histochemical Society and serves on several advisory councils including the Leadership Advisory Council for the Advanced Regenerative Manufacturing Institute. He is the Co-Director of the upcoming Gordon Research Conference titled "Advanced Cell and Tissue Biomanufacturing" planned for June 2023.



PALL Pall Corporation

BRYAN POLTILOVE

Operating Director at BroadOak

His role is to investigate ways to convert challenges into business opportunities, and he helps drive innovation processes within Cytiva, Pall Biotechnology, and other Danaher operating companies. He is the Past-President of The Histochemical Society and serves on several advisory councils including the Leadership Advisory Council for the Advanced Regenerative Manufacturing Institute. He is the Co-Director of the upcoming Gordon Research Conference titled "Advanced Cell and Tissue Biomanufacturing" planned for June 2023.



BroadOak

Also in the „European Startups: Undervalued opportunities for US Investors?! panel discussion.

Topic: How can the industry successfully deal with the impact of inflation and the supply chain issues?

ADRIANA KRASNIANSKY

Research Manager

Adriana supports the Research team at Rock Health as an associate. Previously, Adriana worked as a researcher and strategist for health-centered organizations including C-TAC (the Coalition to Transform Advanced Care) and the Massachusetts Office of Elder Affairs. Adriana earned her bachelor's degree in business from Fordham University and her master's degree in health equity and aging studies from Harvard University. She was also named a Petrie-Flom Fellow in bioethics, biotechnology, and health law policy. Adriana has published research and led projects related to technology ethics, community-based digital health programs, and virtual care services for Medicare populations.



ROCK
HEALTH

Our speakers... up close:

More DxPx Speakers

Topic: Establishing a New Diagnostics
Gold Standard in Biomarkers.

DR. FRANK PEACOCK

Chief Medical Officer of AseptiScope®

Frank Peacock IV, MD, FACEP, FACC is a Professor of Emergency Medicine and Vice Chair of Research for the department of Emergency Medicine at the Baylor College of Medicine, in Houston, Texas. With over 600 peer reviewed publications, predominantly on heart failure and acute coronary syndromes, Dr. Peacock is also the co-editor of the textbooks Cardiac Emergencies, Short Stay Management of Heart Failure, Short Stay Management of Chest Pain, and Short Stay Management of Atrial Fibrillation.



DONNA EDMONDS

CEO, BRAINBox Solutions Inc.

Topic: Establishing a New Diagnostics Gold Standard in Biomarkers

Donnas Edmonds has 30+ years of healthcare experience. She served in senior management roles for 10 diagnostic companies and has a key leadership in two company exits. She is a recognized leader in Cardiovascular Diagnostics. She is also the past Governor-appointed member of the Virginia Biotechnology Research Park Authority (9 yrs) and is currently on the Boards of Mid Atlantic-based BioHealth Innovation dedicated to translating science into market entry products, as well as several Life Sciences entities.



CHRISTOPH BRANDENBERGER

Managing Director Healthcare and Life Sciences, Brown Gibbons Lang & Company

He is a healthcare and life sciences investment banker with a background of over 20 years in all aspects of operations planning, financial management, and general management for Diagnostics, Research Tools, CRO, CDMO, and Medical Devices companies. He has a very strong international business background that includes both U.S. and trans-European experience.



MODERATOR



Topic: Post-merger integrations in life sciences. The good, the bad, the ugly.

SRIDHAR IYENGAR, PHD

CEO & Founder, Elemental Machines

A serial entrepreneur in IoT, medical devices, and wearables, Sridhar was a founder of Misfit, makers of elegant wearable products acquired by Fossil in 2015. Prior to Misfit, he founded AgaMatrix based on his Ph.D. research, a blood glucose monitoring company that made the world's first iPhone-connected medical device. Sridhar holds more than 50 U.S. and international patents and received his Ph.D. from Cambridge University as a Marshall Scholar.



INGO CHAKRAVARTY

President & CEO, Mesa Biotech of Thermo Fisher Scientific

Ingo has over 25 years of experience building and leading high performance organizations in healthcare. He was President and CEO of Mesa Biotech, a rapid-PCR technology and testing company in infectious disease. Mesa was acquired by Thermo Fisher for up to \$550M in February 2021. He spent the last two decades building global business, holding senior leadership positions at Navican Genomics, GenMark Diagnostics, Gen-Probe, Roche and Ventana Medical Systems.



There's more!

Discover additional speakers from:



Recap previous events with our

DxPx Impressions



Future innovations. Impacting lives of patients today.

About Diagnostics4Life

We are honored to present Diagnostics4Life, the charity platform of DxPx. With the social engagement and helpfulness of our stakeholders, founders, and investors, we also like to share this endeavor with you. As DxPx Conference teams up with different kinds of stakeholders, e.g. founders and investors, we would like to encourage our participants to increase everybody's impact on our charity projects. It is launched with the vision to support communities that need further innovation.

Now, we present to you our partner charity, Conquer Cancer™

Creating a World of Difference with Diagnostics4Life and Conquer Cancer™, the ASCO Foundation

In 2022, we are working with Conquer Cancer, the American Society of Clinical Oncology's foundation, for this initiative of raising awareness on conquering cancer and spreading the value our industries provide to our society. Every DxPx participant will have the opportunity to foster our chosen DxPx charity, Conquer Cancer, as part of the income from ticket sales and sponsoring from our industry partners will be donated. We are hopeful that these proceeds will help create a world of difference in cancer care and help patients who heavily depend on diagnostics to improve their quality of life



More about Conquer Cancer™:

Conquer Cancer™ funds research for every cancer, every patient, everywhere. Since 1984, its Grants & Awards program has awarded more than \$146 million through more than 2,400 grants and awards to improve cancer care and accelerate breakthroughs in clinical and translational oncology research. Conquer Cancer™ donors support vital programs needed to deliver the highest quality, equitable patient care and share a vision of a world where cancer is prevented or cured, and every survivor is healthy. For more information, visit www.conquer.org.

Finally, an honorable mention should be given to our charity partner in Europe, the parents' initiative for children with heart disease in Cologne (Elterninitiative herzkrankter Kinder Köln, e.V. (EI)).



How it all began

The idea behind 42PLUS1 is simple. 42 is known as the answer to the ultimate question of life, the universe, and everything. This excerpt comes from the movie „Hitchhiker’s Guide to the Galaxy“. About the big big big startup universe, we all look for a specific answer to one question: “How am I to find investors and become visible among the many stars of the ever-growing startup universe?” And this is why our team set up 42PLUS1.

42PLUS1 in a nutshell

42PLUS1, the highest prized pitch award in the diagnostics, digital health, precision medicine and life science tools galaxy, takes place annually and is in its second year now. What kind of startups are we looking for? Those who are disrupting technology and moving in the fields of the four interrelated industries and are in the early-stage development, with an entrepreneurial spirit with the analytical minds of life science enthusiasts, enabling innovations daily are more than welcome to join!

Starting in 2021, we host the grand finale of 42PLUS1 where the eight finalists pitch their innovations during the DxPx Conference.

How 42PLUS1 and DxPx work together

With 42PLUS1, we are constantly guiding startups and growth companies to have the biggest impact on the world and humanity. We arrange the 42PLUS1 pitch award at the DxPx Conference because aside from hearing the pitches live, it is a great opportunity for our dear startups and growth companies to meet and engage with the investors focusing on these four interrelated industries. The well-curated jurors of the 42PLUS1 pitch award are also experts and executives from the four interrelated industries who are qualified to give feedback and input to the finalists.

We wish you the best in the upcoming 42PLUS1 pitch award this year! On behalf of the entire DxPx Team, I would like to thank our knowledge partners, sponsors, accelerators, and media partners who helped us in pioneering this competition and for making it further grow. This is a big leap into the future for all of us!

Best,
Lena Ehrenpreis
42PLUS1 & DxPx Initiator

A handwritten signature in black ink, appearing to read "Lena Ehrenpreis".

338
STARTUPS

45
COUNTRIES

1
SATELLITE FINALE
AT DxPx US

8
FINALISTS
1
GRAND FINALE
AT DxPx EU

\$2,000,000
IN CONVERTIBLES



We're over the moon for highly-skilled jurors who supported us from day 1!

Big applause for our jurors



Jens Baas

Chairman of the Board



Reetika Bhardwaj
Associate



Rainer Christine
Managing Partner



Matthias Essenpreis
CTO



Eric Fritz
Partner



Sascha Fritz

Investment Principal



Bernd Goergen
Partner



Douwe Jippes
Managing Partner



Christoph Massner
Investment Team



Wouter Meuleman
Partner



Tobias Silberzahn
Partner



Sebastian Stamm
Principal



Erika Stanzl
Associate Partner



Dirk Voelkel
President Innovation



Roy Wiesner
Managing Director



André Zimmermann
Partner

Interested in joining our DxPx galaxy as a juror?

Happy to talk!

l.ehrenpreis@silversky-ls.com

Recap previous events with our

DxPx Impressions





SILVERSKY

LIFESCIENCES



We have one goal. Bringing our industry together.

Everyone at SLS has one very specific goal always firmly in mind – to bring our industry together. Whether startups, SMEs, large corporations or investors. We have been building our network in diagnostics, research tools and precision medicine for almost 15 years now and we are not finished yet. We offer this network to all our clients to find the right partners with whom they can develop their business

Funding innovation

We offer targeted support in the implementation and financing of your innovation projects. If you would like to know whether your R&D project or investment plan is eligible for funding, you can have your project checked simply, quickly and securely with our free funding check. We will also tell you whether the project is suitable for ZIM or whether another funding programme needs to be selected.

Finding investors

We closed our first investment round in 2008. During the Lehman crisis. We successfully closed three rounds during the Covid pandemic. And many more in between for own companies and clients in the diagnostics and research tool space.

We have worked for over a decade to build a personal network to investors in Europe, China and the US. And yet we believe match-making with investors should be even more effective and easier for our companies... and our clients!

Therefore we initiated and host an annual, international investor partnering conference.

You have not had enough after 2 days of DxPx?

Last but not least - our legendary **DxPx ROOFTOP AFTERPARTY**



GET TO KNOW BEAUTIFUL CHICAGO BY NIGHT

and have a look over the city from our legendary rooftop reception..

ENJOY GOOD DRINKS AND HEAVENLY SNACKS

after an eventful day with so many impressions.



NETWORK IN A RELAXED ATMOSPHERE

to once again get the most out of your day.



July 27th 7:00 pm

Location:

VU Rooftop Bar

Hilton's McCormick Place

133 E Cermak

Chicago IL 60616

"Fantastic event with a legendary rooftop party over Düsseldorf. Relaxed atmosphere to rub shoulders and share drinks with Medtech, start-ups, investors and hospital leadership."

Devlin Hannon, Boston Scientific
Endoscopy Business Unit Director - Central
Western Europe

Always happy to help

Your first Contacts



DxPx Project Manager

JESSICA STOLZENBERG

"Generalist who oversees the organization's ongoing operations and procedures and being responsible for the efficiency of the overall business."



DxPx & 42PLUS1 Initiator

LENA EHRENPREIS

"Fostering innovation in healthcare by initiating the 42PLUS1 Pitch Award, after getting to know the startup game with her own company."

You can always call or visit our main offices in Dusseldorf:

SLS Partnering GmbH
Dusseldorf, Brunnenstr. 23
+49 211 30270813
info@dpx-conference.com

Finally, feel free to reach us via our social media:

LinkedIn, Facebook, & YouTube:

DxPx Conference, 42PLUS1
Silversky Lifesciences, SLS Partnering

Subscribe to our newsletter:



Save the dates 2022



DxPx US

3 days in person:

AACC Clinical Lab Expo,
Chicago, USA

Jul 26th - 28th 2022

2 weeks digital partnering:

Jul 14th - Jul 25th



DxPx EU

2 days in person:

Maritim Hotel, Dusseldorf, Ger.

Nov 15th - 16th 2022

2 weeks digital partnering:

Nov 4th - Nov 14th



World Series of Industry and Investor Partnering Conferences

42PLUS1 Grand Finale

at DxPx EU
Nov 15th 2022



Nov 15th - Nov 17th
Dusseldorf Germany

Your next chance to win \$2,000,000 in convertible loans
42PLUS1 US Satellite Event

May 16th - Jun 27th: Submissions are open
Jul 11th: Finalists Announcement
Jul 27th: 42PLUS1 Satellite Finale

The winner will be invited to the DxPx EU for
the 42PLUS1 grand finale
Nov 15th, 2022 in Dusseldorf, Germany

Important Dates for the finale:
Sep 5th - Oct 17th: Submissions are open
Oct 31st: Finalists announcement

Imprint

Publisher

SLS Partnering GmbH
Brunnenstr. 23
40023 Düsseldorf
Germany
Phone: +49 211 302 708 13
info@sls-partnering.com
www.sls-partnering.com



Editing and design

SLS Partnering GmbH
Mirko Stange, Lena Ehrenpreis





Biotech AG

ENABLING COMPLEX SOLUTION ANALYTICS

A NEW QC GOLD STANDARD FOR CELL-THERAPIES



FAST



AUTOMATED



COMPLEX SAMPLES



STABLE



LABEL-FREE



MULTIPLEX

www.lino-biotech.com